Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00928837 · ClinicalTrials.gov registry record · NA

Study of Flavocoxid (Limbrel) Versus Naproxen in Subjects With Moderate-Severe Osteoarthritis of the Knee

A NA study, sponsored by Primus Pharmaceuticals.

Completed
Registry status
NA
Development phase
350
Enrollment target

NCT00928837: Completed NA study, sponsored by Primus Pharmaceuticals.

NCT00928837 is a NA study that has completed, run by Primus Pharmaceuticals. The registered enrollment target is 350 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (75% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00928837, a NA study, has completed, sponsored by Primus Pharmaceuticals.

COMPLETED
Registry status
NA
Development phase
350 participants
Enrollment target

Study Summary

The purpose of the study is to compare the efficacy and safety of flavocoxid (Limbrel) with Naproxen and placebo in OA of the knee.

Primary Outcome

comparison of short WOMAC and timed walk

Interventions

  • OTHER Placebo
  • DRUG Naproxen
  • DIETARY_SUPPLEMENT Flavocoxid 500 mg
  • OTHER flavocoxid 250 mg

Trial Details

FieldValue
Enrollment Target 350 participants
Start Date 2006-03
Est. Completion 2007-09
Phase NA
Primus Pharmaceuticals

15 total trials

What the finished NCT00928837 record still lists

NCT00928837 is an interventional study that assigns participants to a tested intervention. The registered 350 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (75% lower).

The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.

NCT00928837 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00928837 about?

NCT00928837 is a clinical study titled "Study of Flavocoxid (Limbrel) Versus Naproxen in Subjects With Moderate-Severe Osteoarthritis of the Knee". The purpose of the study is to compare the efficacy and safety of flavocoxid (Limbrel) with Naproxen and placebo in OA of the knee.

What is the current status of trial NCT00928837?

This trial is currently completed. It is a NA study. The enrollment target is 350 participants. The study started on 2006-03. Estimated completion is 2007-09.

What interventions are being tested in trial NCT00928837?

The interventions under investigation include: Placebo (OTHER), Naproxen (DRUG), Flavocoxid 500 mg (DIETARY_SUPPLEMENT), flavocoxid 250 mg (OTHER).

Who is sponsoring clinical trial NCT00928837?

This trial is sponsored by Primus Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00928837's enrollment target sits among peer trials

350 292nd of 2000 higher than 1,699 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00900575 · 350 participants · NA

    Cervical Cancer Detection Using Optical Spectroscopy

  • NCT01627821 · 350 participants · NA

    Evaluation of the Jarvik 2000 Left Ventricular Assist System With Post-Auricular Connector--Destination Therapy Study

  • NCT02357654 · 350 participants · Phase 4

    GnRH for Luteal Support in IVF/ICSI/FET Cycles

  • NCT03997370 · 350 participants · Phase 1

    Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00928837, the US trial registry maintained by the National Library of Medicine. NCT00928837 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.